May Aldaabil, MD | |
2300 Southwood Dr, Nashua, NH 03063-1818 | |
(603) 577-4000 | |
Not Available |
Full Name | May Aldaabil |
---|---|
Gender | Female |
Speciality | Rheumatology |
Experience | 31 Years |
Location | 2300 Southwood Dr, Nashua, New Hampshire |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306243910 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RR0500X | Internal Medicine - Rheumatology | MD20373 (Maine) | Secondary |
207RR0500X | Internal Medicine - Rheumatology | EL11701 (New Hampshire) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
Kent County Memorial Hospital | Warwick, RI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.
MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the fourth quarter and year ended October 31, 2013.
A new method of characterizing breast lesions found during an MRI exam could result in fewer biopsies of benign tumors with the benefits of reduced pain and expense for patients and providers, according to a paper that will be presented today (Sunday, Nov. 30) at the annual meeting of the Radiological Society of North America (RSNA).
Today, as AstraZeneca reports 2 billion doses of the COVID-19 vaccine released for supply University of Oxford scientists explain how it has been possible to produce so much of the vaccine in less than a year, and the unprecedented strategy used to improve international equity of access.
PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.
› Verified 7 days ago
Entity Name | Mary Hitchcock Memorial Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.
MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the fourth quarter and year ended October 31, 2013.
A new method of characterizing breast lesions found during an MRI exam could result in fewer biopsies of benign tumors with the benefits of reduced pain and expense for patients and providers, according to a paper that will be presented today (Sunday, Nov. 30) at the annual meeting of the Radiological Society of North America (RSNA).
Today, as AstraZeneca reports 2 billion doses of the COVID-19 vaccine released for supply University of Oxford scientists explain how it has been possible to produce so much of the vaccine in less than a year, and the unprecedented strategy used to improve international equity of access.
PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.
› Verified 7 days ago
Entity Name | Dartmouth-hitchcock Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.
MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the fourth quarter and year ended October 31, 2013.
A new method of characterizing breast lesions found during an MRI exam could result in fewer biopsies of benign tumors with the benefits of reduced pain and expense for patients and providers, according to a paper that will be presented today (Sunday, Nov. 30) at the annual meeting of the Radiological Society of North America (RSNA).
Today, as AstraZeneca reports 2 billion doses of the COVID-19 vaccine released for supply University of Oxford scientists explain how it has been possible to produce so much of the vaccine in less than a year, and the unprecedented strategy used to improve international equity of access.
PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
May Aldaabil, MD Po Box 810, Hanover, NH 03755-0810 Ph: (603) 308-1453 | May Aldaabil, MD 2300 Southwood Dr, Nashua, NH 03063-1818 Ph: (603) 577-4000 |
News Archive
The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.
MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the fourth quarter and year ended October 31, 2013.
A new method of characterizing breast lesions found during an MRI exam could result in fewer biopsies of benign tumors with the benefits of reduced pain and expense for patients and providers, according to a paper that will be presented today (Sunday, Nov. 30) at the annual meeting of the Radiological Society of North America (RSNA).
Today, as AstraZeneca reports 2 billion doses of the COVID-19 vaccine released for supply University of Oxford scientists explain how it has been possible to produce so much of the vaccine in less than a year, and the unprecedented strategy used to improve international equity of access.
PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.
› Verified 7 days ago
Christopher Michael Riccio, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-594-6337 Fax: 603-594-6330 | |
Dr. Mark Liebling, Rheumatology Medicare: Medicare Enrolled Practice Location: 166 Kinsley St Ste 301, Nashua, NH 03060 Phone: 603-883-5673 Fax: 603-689-1343 | |
Dr. Chengta Richard Dai, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 168 Kinsley Street, Suite 20, Nashua, NH 03060 Phone: 603-578-9363 Fax: 603-578-9539 | |
Dr. William Stephan, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 168 Kinsley St, Nashua, NH 03060 Phone: 603-889-4131 | |
Ihab M Ziada, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 173 Daniel Webster Hwy, Nashua, NH 03060 Phone: 603-891-4500 | |
Ajay K Sharma, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2039 Fax: 603-882-5656 | |
Dr. Gianfranco Tulliano, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2045 Fax: 603-577-5644 |